drugset
drugset / Trial / NCT03729258

Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis.

NCT03729258 ↗

Phase 3 Unknown 100 enrolled Neutec Ar-Ge San ve Tic A.Ş
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to compare the efficacy and safety of cefpodoxime 200 mg immediate (b.i.d) and cefpodoxime 400 mg modified release (q.d) tablet formulations in the treatment of acute bacterial rhinosinusitis.

Timeline

Start
2019-05-15
Primary completion
2023-10-01
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cefpodoxime Small molecule 200 mg —
Comparator Cefpodoxime Small molecule 400 mg —

Indications

sinusitis